^
Association details:
Biomarker:FGFR1 amplification
Cancer:Breast Cancer
Drug Class:Aromatase inhibitor
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Title:

CCND1 and FGFR1 gene amplifications are associated with reduced benefit from aromatase inhibitors in metastatic breast cancer

Published date:
09/02/2020
Excerpt:
Presence of CCND1 and/or FGFR1 amplification is associated with worse outcomes of AI therapy in patients with metastatic BC.
DOI:
10.1007/s12094-020-02481-w